Document is current
Any future updates will be listed below
-
Authors
Xi, Li
Garcet, Sandra
Ye, Zhan
Hung, Kenneth
Hassan-Zahraee, Mina
Kieras, Elizabeth
Krueger, James G.
Hyde, Craig
Peeva, Elena
- License Information
-
More Information
Article History
Received: 13 July 2022
Accepted: 14 October 2022
First Online: 17 November 2022
Competing interests
: LX, ZY, CH, MHZ, KH, EMK and EP were full-time employees of Pfizer at the time of this study and may therefore hold stocks in Pfizer. S.G. state no conflicts of interest. J.G.K. receives Consultant/honoraria: AbbVie, Aclaris, Allergan, Almirall, Amgen, Arena, Aristea, Asana, Aurigene, Biogen Idec, Boehringer Ingelheim, Bristol-Myers Squibb, Escalier, Galapagos, Janssen, Lilly, MoonLake Immunotherapeutics, Nimbus, Novartis, Pfizer, Sanofi, Sienna Biopharmaceuticals, Sun Pharma, Target-Derm, UCB, Valeant, Ventyx; Grant support (to The Rockefeller University): AbbVie, Akros, Allergan, Amgen, Avillion, Biogen, Botanix, Boehringer Ingelheim, Bristol-Myers Squibb, Exicure, Innovaderm, Incyte, Janssen, Kyowa Kirin, Lilly, Nimbus Lackshmi, Novan, Novartis, PAREXEL, Pfizer, Regeneron, UCB, Vitae Pharmaceuticals.
